Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor)

Miller1, Keenan, Willette

  • 1R&D Division, SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA.

Drug Discovery Today
|August 10, 2000
PubMed

Insights

Small molecules targeting integrin alphavbeta3 show therapeutic promise for diseases like osteoporosis and cancer. Recent research highlights potent antagonists effective in disease models, demonstrating their potential for treatment.

Area of Science:

  • Integrin biology
  • Pharmacology
  • Disease therapeutics

Background:

  • Integrin alphavbeta3 is implicated in various human diseases, including osteoporosis, restenosis, arthritis, cancer, and ocular conditions.
  • Targeting integrin alphavbeta3 offers a potential therapeutic strategy for these diseases.

Purpose of the Study:

  • To review recent advancements in the identification of small-molecule integrin alphavbeta3 antagonists.
  • To emphasize proof-of-concept studies utilizing these antagonists in vivo for disease treatment.

Main Methods:

  • Identification of potent small-molecule antagonists.
  • Evaluation of antagonist activity in relevant disease models.
  • In vivo proof-of-concept studies.

Main Results:

  • Numerous potent small-molecule alphavbeta3 antagonists have been identified.
  • Several antagonists demonstrate efficacy in preclinical disease models.
  • These findings support the therapeutic potential of alphavbeta3 antagonism.

Conclusions:

  • Small-molecule integrin alphavbeta3 antagonists represent a promising therapeutic avenue.
  • Further development and in vivo studies are crucial for translating this potential into clinical treatments.

Related Concept Videos

Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...